Showing 2261-2270 of 3329 results for "".
- Hydrafacial Opens Their CONNECT Certification Program to All Aesthetic Professionalshttps://modernaesthetics.com/news/hydrafacial-opens-their-connect-certification-program-to-all-aesthetic-professionals/2473079/The HydraFacial Company is expanding the HydraFacial CONNECT certification program, making it available to aesthetic professionals nationwide. This past month, the program successfully graduated its first class of CONNECT Masters, the highest distinction in the certification progr
- It's A Deal: Eirion Therapeutics, Shanghai Haohai Biological Technology Close $40M Series A Investment and Licensing Dealhttps://modernaesthetics.com/news/its-a-deal-eirion-therapeutics-inc-shanghai-haohai-biological-technology-closes-40m-series-a-investment-and-licensing-deal/2473070/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- Evolus’ Jeuveau Can Stay on U.S. Market For Nowhttps://modernaesthetics.com/news/evolus-jeuveau-gets-stay-of-execution/2473061/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Revance: ePosters Showcase Data for DaxibotulinumtoxinA and RHA Line at Maui Dermhttps://modernaesthetics.com/news/revance-eposters-showcase-data-for-daxibotulinumtoxina-and-rha-line-at-maui-derm/2473053/Three ePosters presented at the Maui Derm for Dermatologists 2021 meeting feature data for DaxibotulinumtoxinA for Injection and the RHA® Collection of hyaluronic acid based dermal fillers, both from Revance Therapeutics. Revance repo
- Business News: Dominion Aesthetic Technologies Closes $23.7 Million Series B Financinghttps://modernaesthetics.com/news/business-news-dominion-aesthetic-technologies-closes-237-million-series-b-financing/2473052/Dominion Aesthetic Technologies, developers of EON, closed Series B financing, raising a total of $23.7 million. The series B funding will accelerate the manufacturing and commercialization of EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasi
- RealSelf Adds One Million Arabic-speaking Monthly Users With Tajmeeli.com Acquisitionhttps://modernaesthetics.com/news/realself-adds-1-million-arabic-speaking-monthly-users-with-tajmeelicom-acquisition/2473043/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- Merz and Candela Announce New Collabhttps://modernaesthetics.com/news/merz-and-candela-announce-new-collab/2473041/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales reprentatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally integr
- HydraFacial To Go Public After SPAC Dealhttps://modernaesthetics.com/news/hydrafacial-to-go-public-after-spac-deal/2473028/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Promising Results from Dysport Dose Escalation Studyhttps://modernaesthetics.com/news/promising-results-from-dysport-dose-escalation-study/2473018/Top-line results from a Phase 2 dose escalation study show that significantly more subjects treated with Dysport® at all four doses achieved a composite two grade improvement responder rate than those treated with placebo at one month. The study accessed the duration of ef
- Avita Therapeutics, Houston Methodist Research Institute Join Forces to Develop New Ways to Rejuvenate Aging Skinhttps://modernaesthetics.com/news/avita-therapeutics-houston-methodist-research-institute-join-forces-to-develop-new-ways-to-rejuvenate-aging-skin/2473017/Avita Therapeutics’ is partnering with Houston Methodist Research Institute (HMRI) to identify novel approaches to reverse skin aging and rejuvenate skin with the potential for broader applicability such as scar revision and wound healing. The project seeks to establish